Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. has been granted an extension until May 10, 2027, to meet Nasdaq's minimum $1.00 closing bid price requirement. The company's listing was transferred to The Nasdaq Capital Market, effective November 12, 2026. To regain compliance, Rani Therapeutics must achieve a closing bid price of at least $1.00 for 10 consecutive business days. The company is exploring options, such as a reverse stock split, to address the deficiency, though there is no assurance of success.

Rani Therapeutics Holdings, Inc. reported a net loss of $16.4 million for the six months ended June 30, 2026, a reduction from $24.0 million in the prior year period. Contract revenue saw a substantial increase to $3.4 million. The company concluded the period with $53.4 million in cash, cash equivalents, and marketable securities, which is projected to cover operations for at least the next twelve months. Despite reduced operating expenses, net cash used in operating activities increased, and the company anticipates continued losses and a need for future financing.

Rani Therapeutics reported its second quarter 2026 financial results, alongside significant corporate and clinical updates. The company announced positive initial Phase 1a data for RT-114, demonstrating oral bioavailability greater than 150% compared to subcutaneous dosing, and has dosed the first participants in the Phase 1a expansion cohort. Rani also completed a $20 million registered direct offering, expanded its obesity pipeline through a new collaboration with PegBio, and made key management appointments. For Q2 2026, the net loss decreased to $8.4 million from $11.2 million year-over-year, and contract revenue reached $1.7 million.

Rani Therapeutics Holdings, Inc. announced the appointment of Michelle Gilson to its Board of Directors, effective August 1, 2026. Ms. Gilson will also assume the role of chair of the Audit Committee. She brings extensive financial and biotechnology experience, having most recently served as Chief Financial Officer of Arcellx, Inc. until its acquisition by Gilead Sciences, Inc. in April 2026, and previously as a Senior Biotechnology Equity Research Analyst.

Rani Therapeutics granted an equity award in the form of a stock option to purchase 2,000,000 shares of its Class A common stock to Nicholas Maestas, the company's new Chief Financial Officer. This award, granted on July 17, 2026, serves as an inducement for his employment. The stock option has an exercise price of $0.6973 per share and vests over four years, subject to continued service.

Rani Therapeutics reported positive initial Phase 1a data for RT-114, an orally administered GLP-1/GLP-2 dual agonist. The study demonstrated that oral RT-114 achieved systemic exposure and bioavailability greater than 150% compared to a matched subcutaneous dose of PG-102, with a favorable safety and tolerability profile. The company is expanding the Phase 1a study to further characterize the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity, expected to start in 2026 with data in 2027.

Rani Therapeutics Holdings, Inc. has announced a research and development collaboration with PegBio Co., Ltd. The partnership aims to explore the oral delivery of multiple novel candidates from PegBio's obesity and metabolic disease pipeline using Rani's proprietary RaniPill® platform. This collaboration is expected to expand Rani's obesity franchise and advance promising molecules into clinical development, reflecting confidence in the versatility of the RaniPill® technology.

Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas Maestas as its new Chief Financial Officer, effective immediately. Maestas brings over a decade of financial leadership experience from clinical-stage biotechnology companies, including his previous role as CFO at Tempest Therapeutics. He succeeds Svai Sanford, who departed in May 2026 to pursue other opportunities. The company highlighted Maestas's expertise in biopharma capital markets and corporate strategy.

Rani Therapeutics Holdings, Inc. entered into a securities purchase agreement with institutional investors to raise approximately $20.0 million in gross proceeds. The offering includes 12,476,637 shares of Class A common stock at $1.07 per share and pre-funded warrants for 6,214,953 shares at $1.0699 per warrant. The closing is expected around May 27, 2026, with placement agents receiving a 6.0% cash fee.

Rani Therapeutics announced a registered direct offering to raise approximately $20.0 million in gross proceeds. The offering includes the sale of 12,476,637 shares of Class A common stock at $1.07 per share and 6,214,953 pre-funded warrants at $1.0699 per warrant. A sovereign wealth fund is leading the investment, alongside other new and existing healthcare-focused funds, with the closing expected around May 27, 2026.